Suramin prevents neovascularisation and tumour growth through blocking of basic fibroblast growth factor activity.
about
Gentisic acid, a compound associated with plant defense and a metabolite of aspirin, heads a new class of in vivo fibroblast growth factor inhibitorsA Second WNT for Old Drugs: Drug Repositioning against WNT-Dependent CancersLeads for development of new naphthalenesulfonate derivatives with enhanced antiangiogenic activity: crystal structure of acidic fibroblast growth factor in complex with 5-amino-2-naphthalene sulfonateHuman bladder cancer invasion model using rat bladder in vitro and its use to test mechanisms and therapeutic inhibitors of invasionPhase I trial of intravesical Suramin in recurrent superficial transitional cell bladder carcinomaAngiogenesis in urological malignancy: prognostic indicator and therapeutic target.General aspects of anti-angiogenesis and cancer therapy.Anti-insulin-like growth factor-I activity of a novel polysulphonated distamycin A derivative in human lung cancer cell lines.Vascularity, angiogenesis and angiogenic factors in leukemias and myelodysplastic syndromes.A structure-activity analysis of antagonism of the growth factor and angiogenic activity of basic fibroblast growth factor by suramin and related polyanionsCurrent status and perspective of antiangiogenic therapy for cancer: urinary cancer.Anti-angiogenic drugs: from bench to clinical trials.Heparanase: a target for drug discovery in cancer and inflammation.Noncytotoxic suramin as a chemosensitizer in patients with advanced non-small-cell lung cancer: a phase II study.Modulation of fibroblast growth factor-2 receptor binding, dimerization, signaling, and angiogenic activity by a synthetic heparin-mimicking polyanionic compound.Antiangiogenic anticancer strategy based on nanoparticulate systems.Glycosylation alterations in lung and brain cancer.Combined treatment with paclitaxel and suramin prevents the development of metastasis by inhibiting metastatic colonization of circulating tumor cells.Heparanase 1 involvement in prostate physiopathology.Inhibition of angiogenesis and murine tumour growth by laminarin sulphateIntravital microscopic characterization of suramin effects in an orthotopic immunocompetent rat model of pancreatic cancer.Suramin inhibits not only tumor growth and metastasis but also angiogenesis in experimental pancreatic cancer.Dihydroxy-2,5 benzenesulphonate (dobesilate) elicits growth arrest and apoptosis in glioma cells.Increased gene expression for VEGF and the VEGF receptors KDR/Flk and Flt in lungs exposed to acute or to chronic hypoxia. Modulation of gene expression by nitric oxide.Manipulation and exploitation of the tumour environment for therapeutic benefit.Bladder cancer angiogenesis, its role in recurrence, stage progression and as a therapeutic target.Vascular endothelial growth factor in pulmonary hypertension.Suramin inhibits C6 glioma-induced angiogenesis in vitro.Centrosome reorientation in regenerating endothelial monolayers requires bFGF.Dobesilate diminishes activation of the mitogen-activated protein kinase ERK1/2 in glioma cellsAdenovirus-mediated gene transfer of fibroblast growth factor-1: angiogenesis and tumorigenicity in nude mice.The basic domain in HIV-1 Tat protein as a target for polysulfonated heparin-mimicking extracellular Tat antagonists.Capillary plexus development in the day five to day six chick chorioallantoic membrane is inhibited by cytochalasin D and suramin.Evaluation of angiogenic inhibitors with an in vivo quantitative angiogenesis method using agarose microencapsulation and mouse hemoglobin enzyme-linked immunosorbent assay.Angiogenic activity of enzymes.Suramin inhibits glioma cell proliferation in vitro and in the brain.
P2860
Q24298832-21A714F9-0B18-4017-B3CD-62797CFAB7E5Q26739665-9D91936B-B30F-4F6D-B59E-D1F3FEC22181Q27640887-7B984C07-1525-4FAF-8022-8DB46692D363Q28350937-34505058-F9D4-404F-A962-8F710CCA6CC7Q33216260-58C04D69-8CFC-460D-9F2E-6591065F3392Q33598141-5C611C06-30CF-411D-A0E1-07129D18789FQ34452066-9E8CC6CC-7F84-4287-97BD-44CE749F4AD2Q35025723-D550B4BE-BD38-4AEF-A79E-F6125684FD4AQ35104368-902CF406-3B0F-4FCE-95A2-6110C8B529E8Q35978481-6EEA0F55-18C5-4683-AFE8-3ACEC0242BF6Q36452714-B5C17A31-CC42-47AB-9E64-B06CBB8153AEQ36465476-2ACFC810-B3E1-4808-B05A-91643CD793AAQ36752653-D23B4ECE-5803-468C-B3B6-FB0D4DB827F4Q37321820-5AAE7E88-E87F-4B9A-8850-E9EDD7A1F7DEQ37365612-A1193B04-056F-4A1D-B0EE-E0798DBE09A0Q37876400-D320C960-EE37-4DEC-A9FD-4BA7F183FBB8Q38366332-F4B0067E-9D84-4118-B51D-7D7BA96D76CCQ38981296-09651518-6DEE-44AF-BAF3-EA33F28887E8Q39138407-D88CAC01-EF9A-4A7C-B9D8-7844C6FEF1F8Q39994817-AB20CAC1-DE05-4466-927D-91A66DF0AB69Q40005836-533C4E69-B911-48D2-B3D6-6C01BFE8C362Q40153390-D8B83B7E-0312-4754-A1CE-7D8E24C888B6Q40340077-64C76C5B-AAE1-4922-93DE-970EEE4D7394Q40342883-4FF2DAF2-A49E-4C91-B9DA-C8DF182DD2DFQ40620925-F9CEE934-1E25-4E24-9AED-F1C3005BF181Q41140293-F8415287-6AEA-43C0-8BE3-2CA15A1740F9Q41157075-54EC377F-0EE0-4510-B7C3-838255B873AFQ41342332-5EC780FE-D21F-4632-808C-880230BF79D9Q41544199-455CE37B-BB96-4D46-A08B-2ECB94081250Q41972376-DD4C8EAD-CB71-4BD9-B2E4-DC805021A6FFQ42835117-1743D30F-07C6-4602-93A7-722070B3CAFFQ43822559-72B210F8-010E-4406-8A07-8963F094C4F6Q44595543-66620E65-46D5-4CE8-80D8-BDA699C247CFQ54943261-1D8CBCF7-EE46-45CB-8788-AA8C90D2661AQ55063277-F10E98FD-0027-4855-8BAE-39E0E42C8F99Q55482459-0FBFD938-FB43-4EBA-9F0C-5B4B05AC089D
P2860
Suramin prevents neovascularisation and tumour growth through blocking of basic fibroblast growth factor activity.
description
1992 nî lūn-bûn
@nan
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
1992年论文
@zh
1992年论文
@zh-cn
name
Suramin prevents neovascularis ...... oblast growth factor activity.
@ast
Suramin prevents neovascularis ...... oblast growth factor activity.
@en
type
label
Suramin prevents neovascularis ...... oblast growth factor activity.
@ast
Suramin prevents neovascularis ...... oblast growth factor activity.
@en
prefLabel
Suramin prevents neovascularis ...... oblast growth factor activity.
@ast
Suramin prevents neovascularis ...... oblast growth factor activity.
@en
P2093
P2860
P356
P1476
Suramin prevents neovascularis ...... oblast growth factor activity.
@en
P2093
P2860
P2888
P304
P356
10.1038/BJC.1992.272
P407
P577
1992-08-01T00:00:00Z